LEGN Live signals | Maximize Profits with Getagraph.com

BUY 979 min ago

@ $52.08

Issued: 15 Apr 2024 @ 14:17

Return: -0.70%

Previous signal: Apr 15 - 13:41

Previous signal: Sell

Return: -1.02 %

Live Chart Being Loaded With Signals

Commentary (15 Apr 2024 @ 16:00):

Stats
Today's Volume	962 528
Average Volume	974 943
Market Cap	9.41B
EPS	$0 ( 2024-03-11 )
Next earnings date	( $-0.230 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-17.59
ATR14	$2.06 (3.99%)

Volume Correlation

Long: -0.21 (neutral)

Short: -0.85 (strong negative)

Signal:(43) Neutral

Legend Biotech Corp Correlation

10 Most Positive Correlations
AQST	0.804

10 Most Negative Correlations
MACQU	-0.813
CFACU	-0.811

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Legend Biotech Corp Correlation - Currency/Commodity

0.77
( moderate )

0.80
( strong )

0.00
( neutral )

0.08
( neutral )

0.72
( moderate )

-0.77
( moderate negative )

Legend Biotech Corp Financials

Annual	2023
Revenue:	$285.14M
Gross Profit:	$120.48M (42.25 %)
EPS:	$-2.94

Q4	2023
Revenue:	$79.46M
Gross Profit:	$41.66M (52.43 %)
EPS:	$-0.800

Q3	2023
Revenue:	$96.01M
Gross Profit:	$52.53M (54.72 %)
EPS:	$-0.340

Q2	2023
Revenue:	$73.33M
Gross Profit:	$40.66M (55.45 %)
EPS:	$-1.140

Financial Reports:

No articles found.

Legend Biotech Corp

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refractory multiple myeloma. The company also has a portfolio of earlier-stage autologous product candidates, which are in Phase I clinical trials for the treatment of gastric cancer and T cell lymphoma. In addition, it is developing CAR-T product candidates targeting CD20/CD22/CD19 for the treatment of non-hodgkins lymphoma, diffuse large B-cell lymphoma, and acute lymphoblastic leukemia. Further, the company has product candidates in early preclinical and clinical development for the treatment of solid tumors as well as infectious diseases. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. Legend Biotech Corporation was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.